Thrombin is a coagulation protein of central importance to hemostasis and wound healing that can be sourced from human blood, bovine blood, and engineered cell lines. Only autologous thrombin lacks the risks of transmitting emergent pathogens or eliciting an immunogenic response. Previous commercial autologous thrombin devices require the use of high concentrations of ethanol to achieve thrombin stability, introducing cytotoxicity risks. A new point of care device for preparing an ethanol-free autologous thrombin serum was investigated. The ethanol-free autologous serum (AS) was prepared using the Thrombinator System (Arthrex, Inc., Naples, FL). A total of 120 devices were tested with the blood of 30 healthy donors to determine the reliability and flexibility of the procedure. AS was prepared from both whole blood (WB) and platelet-poor plasma (PPP). Study endpoints were thrombin activity determined using a coagulation analyzer and formation of cohesive bone graft composites objectively measured using a durometer. The average thrombin activity produced by this system from 24 donors was 20.6 ± 2.7 IU/mL for WB and 13.4 ± 3.8 IU/mL for PPP which correlated to clot times of 3.9 and 5.9 seconds, respectively. The device tolerated use of varying volumes of blood to prepare AS. In addition, the system was able to generate four successive and comparable AS productions. When combined with platelet-rich plasma and bone graft material, cohesive scaffolds were always formed. A new device and method for preparing single donor, ethanol-free, AS with thrombin activity was demonstrated.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296456 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Endothelium Modulates the Prothrombotic Phenotype of Factor V Leiden: Evidence From an Ex Vivo Model.
Arterioscler Thromb Vasc Biol
January 2025
Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Germany.
Background: Clinical expressivity of the thrombophilic factor V Leiden (FVL) mutation is highly variable. Recently, we demonstrated an increased APC (activated protein C) response in asymptomatic FVL carriers compared with FVL carriers with a history of venous thromboembolism (VTE) after in vivo coagulation activation. Here, we further explored this association using a recently developed ex vivo model based on patient-specific endothelial colony-forming cells (ECFCs).
View Article and Find Full Text PDFHemostatic conditions following autologous transfusion of fresh vs stored platelets in experimental endotoxemia: an open-label randomized controlled trial with healthy volunteers.
Res Pract Thromb Haemost
November 2024
Department of Intensive Care Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Article Synopsis
- The study aimed to investigate how fresh and stored platelet concentrates (PCs) behave during inflammation, specifically in a controlled human model of endotoxemia induced by lipopolysaccharide (LPS).
- Researchers found that LPS increased markers related to coagulation and clotting, leading to a generally lower clotting ability in subjects compared to controls, while platelet transfusions improved clotting time and strength in those with endotoxemia.
- Despite these improvements in coagulation, there were no significant differences noted between the effects of fresh versus stored platelets on coagulation parameters like thrombin-antithrombin complex (TATc) or extracellular vesicles (EVs).
Harmony in Healing: Investigating Platelet-Rich Plasma Activation during Acetylsalicylic Acid Treatment.
Int J Mol Sci
October 2024
Department of Oncology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Łukasiewicza 1, 85-821 Bydgoszcz, Poland.
Platelet-rich plasma (PRP) therapy holds promise for treating various clinical conditions. The activation process is crucial in releasing growth factors and cytokines from platelets, enhancing the therapeutic properties of PRP. Standard activation methods involve autologous thrombin or collagen, with variations in efficacy and growth factor release.
View Article and Find Full Text PDFEffect of aspirin on platelet-rich plasma of diabetes mellitus with lower extremity atherosclerosis.
Future Sci OA
December 2024
Department of Endocrinology, General Hospital of Central Theater Command, Wuhan, Hubei Province, 430070, China.
Article Synopsis
- Platelet-rich plasma (PRP) is being studied as a potential treatment for diabetic foot ulcers (DFUs), but the impact of aspirin on its growth factor content is still unclear.
- The study compared PRP from diabetic patients taking aspirin with those not taking it, and found that both had lower growth factor levels than a control group of healthy volunteers.
- Results showed that while aspirin use does not hinder PRP therapy, PRP from healthy individuals is more effective for enhancing the healing of DFUs compared to that from diabetic patients.
Preclinical evaluation of a novel endovascular thrombectomy device in a modified swine model for iliac vein thrombosis.
Heliyon
October 2024
Department of Vascular Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Article Synopsis
- This study aimed to test the safety and effectiveness of a new thrombectomy device (Zylox) for treating iliac vein thrombosis in a specially designed pig model.
- The modified model successfully created bilateral iliac vein thrombosis in 12 pigs, allowing for direct comparison of the Zylox device to an existing device (AcoStream).
- Results showed that although the Zylox group had longer thrombus lengths, it resulted in significantly less blood loss and maintained vein patency without complications, highlighting its potential advantages for future human clinical trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!